ZA9811162B - Treatment with anti-ERBB2 antibodies. - Google Patents
Treatment with anti-ERBB2 antibodies.Info
- Publication number
- ZA9811162B ZA9811162B ZA9811162A ZA9811162A ZA9811162B ZA 9811162 B ZA9811162 B ZA 9811162B ZA 9811162 A ZA9811162 A ZA 9811162A ZA 9811162 A ZA9811162 A ZA 9811162A ZA 9811162 B ZA9811162 B ZA 9811162B
- Authority
- ZA
- South Africa
- Prior art keywords
- treatment
- erbb2 antibodies
- erbb2
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6934697P | 1997-12-12 | 1997-12-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA9811162B true ZA9811162B (en) | 2000-06-07 |
Family
ID=22088358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9811162A ZA9811162B (en) | 1997-12-12 | 1998-12-07 | Treatment with anti-ERBB2 antibodies. |
Country Status (18)
Country | Link |
---|---|
US (11) | US7846441B1 (xx) |
EP (3) | EP1037926B1 (xx) |
JP (7) | JP2002508397A (xx) |
KR (7) | KR20130036367A (xx) |
CN (2) | CN1269839C (xx) |
AR (1) | AR020051A1 (xx) |
AU (1) | AU1908199A (xx) |
BR (1) | BR9815363A (xx) |
CA (2) | CA2730373A1 (xx) |
DK (1) | DK1037926T3 (xx) |
ES (1) | ES2450922T3 (xx) |
HK (2) | HK1030784A1 (xx) |
IL (4) | IL136201A0 (xx) |
NO (2) | NO20002957L (xx) |
NZ (1) | NZ504597A (xx) |
TR (1) | TR200001689T2 (xx) |
WO (1) | WO1999031140A1 (xx) |
ZA (1) | ZA9811162B (xx) |
Families Citing this family (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2697752B1 (fr) | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
US6524832B1 (en) | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
US6972170B1 (en) | 1997-12-01 | 2005-12-06 | Sloan-Kettering Institute For Cancer Research | Markers for prostate cancer |
ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
US6417168B1 (en) | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
US6333348B1 (en) | 1999-04-09 | 2001-12-25 | Aventis Pharma S.A. | Use of docetaxel for treating cancers |
US6316462B1 (en) | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
EP1187632B1 (en) * | 1999-05-14 | 2008-12-03 | Genentech, Inc. | TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
EP1208232A4 (en) * | 1999-06-10 | 2003-01-15 | Sloan Kettering Inst Cancer | PROSTATE CANCER MARKERS |
NZ515975A (en) * | 1999-06-25 | 2004-01-30 | Genentech Inc | Anti-ErbB antibody-maytansinoid conjugates useful in the treatment of tumors characterised by the overexpression of an ErbB receptor |
US20040013667A1 (en) * | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
EP1189634B1 (en) * | 1999-06-25 | 2007-02-28 | Genentech, Inc. | Treating prostate cancer with anti-erbb2 antibodies |
US20030086924A1 (en) * | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
KR100850389B1 (ko) * | 1999-06-25 | 2008-08-04 | 제넨테크, 인크. | 인간화 항-ErbB2 항체 및 항-ErbB2 항체를 사용한치료 방법 |
CA2373721C (en) | 1999-07-02 | 2013-10-15 | Genentech, Inc. | Compounds that bind her2 |
GB9917012D0 (en) * | 1999-07-20 | 1999-09-22 | Pharmacia & Upjohn Spa | Combined preparations comprising antitumor agents |
ES2277683T3 (es) | 1999-07-23 | 2007-07-16 | Glaxo Group Limited | Combinacion de anticuerpo anti-ep-cam con un agente quimioterapeutico. |
WO2001008636A2 (en) * | 1999-08-03 | 2001-02-08 | The Ohio State University | Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein |
PL202369B1 (pl) | 1999-08-27 | 2009-06-30 | Genentech Inc | Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało |
EP1229934B1 (en) | 1999-10-01 | 2014-03-05 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
WO2001055178A2 (en) | 2000-01-25 | 2001-08-02 | Genentech, Inc. | Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
WO2001070268A1 (en) * | 2000-03-22 | 2001-09-27 | Glaxo Group Limited | Pharmaceutical comprising an agent that blocks the cell cycle and an antibody |
CN1429118A (zh) * | 2000-05-15 | 2003-07-09 | 法玛西雅意大利公司 | 芳香酶抑制剂和单克隆抗her2抗体作为抗肿瘤剂 |
EP1282443B1 (en) | 2000-05-19 | 2009-09-02 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
GB0017635D0 (en) * | 2000-07-18 | 2000-09-06 | Pharmacia & Upjohn Spa | Antitumor combined therapy |
US20040138160A1 (en) * | 2001-04-27 | 2004-07-15 | Kenichiro Naito | Preventive/therapeutic method for cancer |
WO2002087618A1 (fr) * | 2001-04-27 | 2002-11-07 | Takeda Chemical Industries, Ltd. | Methode de prevention et de traitement du cancer |
AU2003222664A1 (en) * | 2002-04-18 | 2003-11-03 | Genencor International, Inc. | Production of functional antibodies in filamentous fungi |
CA2487600C (en) * | 2002-05-30 | 2011-07-05 | Toray Industries, Inc. | Adsorbents for immunosuppressive substance, extracorporeal perfusion columns and methods for treating cancer |
AU2002951853A0 (en) * | 2002-10-04 | 2002-10-24 | Commonwealth Scientific And Industrial Research Organisation | Crystal structure of erbb2 and uses thereof |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
GT200500155A (es) * | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
MX2007000723A (es) | 2004-07-22 | 2007-03-12 | Genentch Inc | Composicion de anticuerpos her2. |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
MX2007006529A (es) * | 2004-12-07 | 2007-06-22 | Genentech Inc | Seleccionar pacientes para terapia con un inhibidor her. |
TWI441646B (zh) | 2005-01-21 | 2014-06-21 | Genentech Inc | 帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途 |
EP1846558A2 (en) * | 2005-02-09 | 2007-10-24 | Genentech, Inc. | Inhibiting her2 shedding with matrix metalloprotease antagonists |
CN101163503B (zh) | 2005-02-23 | 2013-05-08 | 健泰科生物技术公司 | 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活 |
TW200642695A (en) * | 2005-03-08 | 2006-12-16 | Genentech Inc | Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs) |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
EP1912680B1 (en) | 2005-06-15 | 2014-11-26 | The Ohio State University Research Foundation | Her-2 peptides |
PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
JP2009511892A (ja) * | 2005-10-11 | 2009-03-19 | ドマンティス リミテッド | 抗体ポリペプチドライブラリーのスクリーニングと選択された抗体ポリペプチド |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
ES2546066T3 (es) | 2006-08-21 | 2015-09-18 | F. Hoffmann-La Roche Ag | Terapia tumoral con un anticuerpo anti-VEGF |
EP2899541A1 (en) | 2007-03-02 | 2015-07-29 | Genentech, Inc. | Predicting response to a HER dimerisation inhbitor based on low HER3 expression |
US8557588B2 (en) * | 2007-03-27 | 2013-10-15 | Schlumberger Technology Corporation | Methods and apparatus for sampling and diluting concentrated emulsions |
WO2008150485A2 (en) * | 2007-05-29 | 2008-12-11 | Wyeth | Erbb2 binding proteins and use thereof |
US20090304590A1 (en) * | 2007-05-29 | 2009-12-10 | Wyeth | Therapeutic compositions and methods |
CA3006428A1 (en) | 2007-06-08 | 2008-12-18 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
WO2009064838A1 (en) * | 2007-11-15 | 2009-05-22 | Amgen, Inc. | Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration |
CA2711843C (en) | 2007-12-20 | 2018-11-13 | Laboratory Corporation Of America Holdings | Her-2 diagnostic methods |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
ES2342646B1 (es) * | 2008-06-02 | 2011-04-26 | Institut De Recerca Hospital Universitari Vall Hebron | Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas. |
BRPI0812682A2 (pt) * | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
JP2012507299A (ja) * | 2008-10-31 | 2012-03-29 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Light標的分子およびその使用 |
SI2752189T1 (sl) | 2008-11-22 | 2017-02-28 | F. Hoffmann-La Roche Ag | Uporaba anti-vegf protitelesa v kombinaciji s kemoterapijo za zdravljenje prsnega raka |
ES2637411T3 (es) | 2008-12-01 | 2017-10-13 | Laboratory Corporation Of America Holdings | Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95 |
BRPI1007321A2 (pt) | 2009-01-15 | 2018-07-10 | Laboratory Corp America Holdings | métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo. |
US20100234283A1 (en) | 2009-02-04 | 2010-09-16 | The Ohio State University Research Foundation | Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use |
CA2755640C (en) | 2009-03-20 | 2018-05-22 | Genentech, Inc. | Bispecific antibody with a single antigen-binding domain specific for both her3 and egfr |
EP2435071A1 (en) | 2009-05-29 | 2012-04-04 | F. Hoffmann-La Roche AG | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
CA2784211C (en) | 2010-02-18 | 2019-12-24 | Genentech, Inc. | Neuregulin antagonists and use thereof in treating cancer |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
NZ604003A (en) | 2010-05-27 | 2015-04-24 | Genmab As | Monoclonal antibodies against her2 |
CN103153339B (zh) | 2010-05-27 | 2021-05-04 | 根马布股份公司 | 针对her2表位的单克隆抗体 |
CA2794731C (en) | 2010-06-18 | 2019-03-19 | Genentech, Inc. | Anti-axl antibodies and methods of use |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
CN101974535B (zh) * | 2010-11-03 | 2012-12-19 | 北京天广实生物技术股份有限公司 | 新型抗ErbB2人源化抗体MIL12的制备及其应用 |
US20130245233A1 (en) | 2010-11-24 | 2013-09-19 | Ming Lei | Multispecific Molecules |
WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
US20140170149A1 (en) | 2011-04-20 | 2014-06-19 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
BR112014003431A2 (pt) | 2011-08-17 | 2017-06-13 | Genentech Inc | anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor |
CN104024432B (zh) * | 2011-08-31 | 2017-02-22 | 基因泰克公司 | 诊断性标志物 |
SI2766040T1 (sl) | 2011-10-14 | 2019-08-30 | F. Hoffmann-La Roche Ag | Pertuzumab, Trastuzumab, Docetaxel in Carboplatin za zdravljenje zgodnjega raka dojke |
WO2013063229A1 (en) | 2011-10-25 | 2013-05-02 | The Regents Of The University Of Michigan | Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells |
EP2785864A2 (en) | 2011-11-30 | 2014-10-08 | F. Hoffmann-La Roche AG | Erbb3 mutations in cancer |
EP2788500A1 (en) | 2011-12-09 | 2014-10-15 | F.Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
RU2014136886A (ru) | 2012-03-27 | 2016-05-20 | Дженентек, Инк. | Диагностика и виды лечения, связанные с ингибиторами her3 |
AU2013331763B2 (en) | 2012-10-15 | 2018-02-15 | Universitat Zurich | Bispecific HER2 ligands for cancer therapy |
EP2719706A1 (en) | 2012-10-15 | 2014-04-16 | Universität Zürich | Bispecific HER2 ligands for cancer therapy |
WO2020074469A1 (en) | 2018-10-08 | 2020-04-16 | Universität Zürich | Her2-binding tetrameric polypeptides |
CA2889298C (en) | 2012-11-30 | 2024-01-02 | Anton Belousov | Identification of patients in need of pd-l1 inhibitor cotherapy |
BR112015024926A2 (pt) | 2013-04-16 | 2017-10-10 | Genentech Inc | composições, artigo de fabricação, métodos para tratar um paciente com câncer, para avaliar uma composição, para avaliar a atividade biológica, para produzir uma composição e para avaliar a fragmentação de uma composição e variante de pertuzumabe |
JP2016526016A (ja) | 2013-05-01 | 2016-09-01 | ファイヴ プライム セラピューティクス インク | がんを治療する方法 |
SG11201608912VA (en) | 2014-04-25 | 2016-11-29 | Genentech Inc | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
CN107614015A (zh) | 2015-05-30 | 2018-01-19 | 豪夫迈·罗氏有限公司 | 治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法 |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
EP3454863A1 (en) | 2016-05-10 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
KR20230149857A (ko) | 2016-07-07 | 2023-10-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
MX2019005144A (es) | 2016-11-04 | 2019-10-14 | Genentech Inc | Tratamiento de cáncer de mama positivo para her2. |
TW201827077A (zh) | 2016-12-28 | 2018-08-01 | 美商建南德克公司 | 晚期her2表現癌症之治療 |
AU2018210312B2 (en) | 2017-01-17 | 2020-03-19 | F. Hoffmann-La Roche Ag | Subcutaneous HER2 antibody formulations |
CN117180422A (zh) | 2017-03-02 | 2023-12-08 | 豪夫迈·罗氏有限公司 | Her2阳性乳腺癌的辅助治疗 |
CA3059241A1 (en) | 2017-04-24 | 2018-11-01 | Genentech, Inc. | Erbb2/her2 mutations in the transmbrane or juxtamembrane domain |
JP2019043214A (ja) | 2017-08-30 | 2019-03-22 | いすゞ自動車株式会社 | ステアリング装置 |
WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
IL303350A (en) | 2020-12-04 | 2023-08-01 | Macrogenics Inc | Preparations containing an antibody against HER2/NEU and their use |
Family Cites Families (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US444960A (en) * | 1891-01-20 | Fence or gate | ||
US4017471A (en) | 1975-09-15 | 1977-04-12 | G. D. Searle & Co. | Immunological compounds |
US4935341A (en) | 1986-06-04 | 1990-06-19 | Whitehead Institute For Biomedical Research | Detection of point mutations in neu genes |
US5169774A (en) | 1984-02-08 | 1992-12-08 | Cetus Oncology Corporation | Monoclonal anti-human breast cancer antibodies |
US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US7838216B1 (en) | 1986-03-05 | 2010-11-23 | The United States Of America, As Represented By The Department Of Health And Human Services | Human gene related to but distinct from EGF receptor gene |
US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
US4994558A (en) | 1986-12-24 | 1991-02-19 | Eli Lilly And Company | Immunoglobulin conjugates |
US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
WO1989010412A1 (en) | 1988-04-18 | 1989-11-02 | Applied Biotechnology, Inc. | Detection of neu gene expression and products |
JP2761543B2 (ja) | 1988-08-17 | 1998-06-04 | 味の素株式会社 | ヒト癌原遺伝子産物に対するモノクローナル抗体及びそれを産生するハイブリドーマ |
WO1990014357A1 (en) | 1989-05-19 | 1990-11-29 | Genentech, Inc. | Her2 extracellular domain |
US5705157A (en) * | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
US6884418B1 (en) | 1989-08-04 | 2005-04-26 | Berlex Laboratories, Inc. | Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy |
JP3859695B2 (ja) | 1989-08-04 | 2006-12-20 | バーレックス ラボラトリーズ インコーポレイテッド | C―erbB―2外部ドメイン:GP75 |
JP2895105B2 (ja) | 1989-09-14 | 1999-05-24 | 株式会社ニチレイ | c‐erbB‐2癌遺伝子産物をイムノアッセイする乳癌の血清診断法とそのキット |
WO1991005264A1 (en) | 1989-09-29 | 1991-04-18 | Oncogenetics Partners | Detection and quantification of neu related proteins in the biological fluids of humans |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
WO1991015230A1 (en) | 1990-04-06 | 1991-10-17 | The Trustees Of The University Of Pennsylvania | Ligand for the neu gene product |
US5578482A (en) | 1990-05-25 | 1996-11-26 | Georgetown University | Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses |
KR100246529B1 (ko) | 1990-12-14 | 2000-04-01 | 스티븐 에이. 서윈. 엠.디. | 수용체 관련된 신호 변환 경로를 위한 키메라 사슬 |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US5367060A (en) | 1991-05-24 | 1994-11-22 | Genentech, Inc. | Structure, production and use of heregulin |
IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
US5834229A (en) | 1991-05-24 | 1998-11-10 | Genentech, Inc. | Nucleic acids vectors and host cells encoding and expressing heregulin 2-α |
EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
US5939531A (en) | 1991-07-15 | 1999-08-17 | Novartis Corp. | Recombinant antibodies specific for a growth factor receptor |
US5514554A (en) | 1991-08-22 | 1996-05-07 | Becton Dickinson And Company | Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy |
US5288477A (en) | 1991-09-27 | 1994-02-22 | Becton, Dickinson And Company | Method for prognosticating response to cancer therapy |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
AU3236793A (en) | 1991-12-12 | 1993-07-19 | Berlex Laboratories, Inc. | Recombinant and chimeric antibodies to c-erbB-2 |
WO1993016185A2 (en) | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
US5660827A (en) | 1992-03-05 | 1997-08-26 | Board Of Regents, The University Of Texas System | Antibodies that bind to endoglin |
AU4025193A (en) | 1992-04-08 | 1993-11-18 | Cetus Oncology Corporation | Humanized C-erbB-2 specific antibodies |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
IT1257898B (it) * | 1992-06-16 | 1996-02-16 | Procedimento ed apparecchiatura per la produzione, in particolare domestica, di bevande. | |
AU687346B2 (en) | 1992-06-30 | 1998-02-26 | Oncologix, Inc. | A combination of anti-erbB-2 monoclonal antibodies and method of using |
AU5355594A (en) | 1992-10-09 | 1994-05-09 | Oncor, Inc. | Methods for the detection of chromosome structural abnormalities by (in situ) hybridization to fixed tissue |
FR2697752B1 (fr) | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
CA2103323A1 (en) | 1992-11-24 | 1994-05-25 | Gregory D. Plowman | Her4 human receptor tyrosine kinase |
US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
US5869445A (en) | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
DE69326937T2 (de) | 1993-03-24 | 2000-12-28 | Berlex Biosciences Richmond | Kombination von Antihormonale und bindende Moleküle zur Krebsbehandlung |
WO1994022478A1 (en) | 1993-03-30 | 1994-10-13 | The Trustees Of The University Of Pennsylvania | PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU) |
US5430620A (en) | 1993-10-08 | 1995-07-04 | Cogent Light Technologies, Inc. | Compact surgical illumination system capable of dynamically adjusting the resulting field of illumination |
US20030108545A1 (en) | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
EP0758196A4 (en) | 1994-05-05 | 1999-05-06 | Univ Pennsylvania | COMPOSITIONS AND METHODS FOR TREATING TUMORS |
US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
US5846749A (en) | 1994-10-12 | 1998-12-08 | The Regents Of The University Of California | Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
EP0711565B1 (en) | 1994-11-10 | 1998-08-26 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Inhibiting growth of leukemic cells by targeting HER-2 protein |
AU4289496A (en) | 1994-12-02 | 1996-06-19 | Chiron Corporation | Method of promoting an immune response with a bispecific antibody |
US5783404A (en) | 1995-04-13 | 1998-07-21 | Amgen Inc. | Methods and compositions for determining HER-2/neu expression using monoclonal antibodies |
US5663144A (en) | 1995-05-03 | 1997-09-02 | The Trustees Of The University Of Pennsylvania | Compounds that bind to p185 and methods of using the same |
JPH11507402A (ja) * | 1995-05-26 | 1999-06-29 | アイジェン・インコーポレーテッド | 分子的にインプリントされた粒状ポリマー及び同ポリマーのペルフロオロカーボン液中における安定化懸濁重合 |
JP3354035B2 (ja) * | 1995-05-31 | 2002-12-09 | 富士写真フイルム株式会社 | ハロゲン化銀カラー写真感光材料の処理方法 |
US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
EP2258726A1 (en) | 1995-06-14 | 2010-12-08 | The Regents of the University of California | High affinity human antibodies to c-erbB-2 |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5783186A (en) * | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
WO1997035012A1 (en) | 1996-03-20 | 1997-09-25 | Board Of Regents, The University Of Texas System | Sensitization of her-2/neu overexpressing cancer cells to chemotherapy |
US5925519A (en) | 1996-06-03 | 1999-07-20 | The Regents Of The University Of California | Genetic alterations associated with prostate cancer |
US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
AU4982097A (en) | 1996-10-18 | 1998-05-15 | Board Of Regents, The University Of Texas System | Anti-erbb2 antibodies |
WO1998018489A1 (en) | 1996-10-30 | 1998-05-07 | The Uab Research Foundation | Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies |
WO1998033914A1 (en) | 1997-01-31 | 1998-08-06 | University Of Rochester | Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response |
US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
EP1064027B1 (en) | 1998-03-27 | 2008-06-18 | Genentech, Inc. | Apo-2 ligand-anti-her-2 antibody synergism |
KR100960211B1 (ko) | 1998-05-06 | 2010-05-27 | 제넨테크, 인크. | 이온 교환 크로마토그래피에 의한 단백질 정제 방법 |
US6316462B1 (en) | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
US6333348B1 (en) | 1999-04-09 | 2001-12-25 | Aventis Pharma S.A. | Use of docetaxel for treating cancers |
EP1187632B1 (en) | 1999-05-14 | 2008-12-03 | Genentech, Inc. | TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
EP1189634B1 (en) | 1999-06-25 | 2007-02-28 | Genentech, Inc. | Treating prostate cancer with anti-erbb2 antibodies |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
PL202369B1 (pl) | 1999-08-27 | 2009-06-30 | Genentech Inc | Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
CN1429118A (zh) | 2000-05-15 | 2003-07-09 | 法玛西雅意大利公司 | 芳香酶抑制剂和单克隆抗her2抗体作为抗肿瘤剂 |
EP1282443B1 (en) | 2000-05-19 | 2009-09-02 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
WO2002045653A2 (en) | 2000-12-08 | 2002-06-13 | Uab Research Foundation | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
CZ20031927A3 (cs) | 2001-01-09 | 2003-10-15 | Merck Patent Gmbh | Farmaceutický prostředek na bázi inhibitorů receptoru tyrosinkinázy a inhibitorů angiogeneze |
JP5069843B2 (ja) | 2002-07-15 | 2012-11-07 | ジェネンテック, インコーポレイテッド | 抗ErbB2抗体を用いる処置に応答性である腫瘍を同定するための方法 |
JP2006516117A (ja) | 2002-11-21 | 2006-06-22 | ジェネンテック・インコーポレーテッド | 抗ErbB2抗体を用いた非悪性疾病または疾患の治療 |
US20060034840A1 (en) | 2004-04-08 | 2006-02-16 | Agus David B | ErbB antagonists for pain therapy |
GT200500155A (es) | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
MX2007000723A (es) | 2004-07-22 | 2007-03-12 | Genentch Inc | Composicion de anticuerpos her2. |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
MX2007006529A (es) | 2004-12-07 | 2007-06-22 | Genentech Inc | Seleccionar pacientes para terapia con un inhibidor her. |
TWI441646B (zh) | 2005-01-21 | 2014-06-21 | Genentech Inc | 帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途 |
CN101163503B (zh) * | 2005-02-23 | 2013-05-08 | 健泰科生物技术公司 | 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活 |
TW200642695A (en) | 2005-03-08 | 2006-12-16 | Genentech Inc | Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs) |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
BRPI0712077A2 (pt) | 2006-05-01 | 2012-01-17 | Genentech Inc | prolongamento de sobrevivência de pacientes com cáncer com niveis elevados de egf ou tgf-alfa |
JP5317084B2 (ja) | 2006-11-08 | 2013-10-16 | 国立大学法人愛媛大学 | π共役環状化合物およびその製造方法 |
EP2899541A1 (en) * | 2007-03-02 | 2015-07-29 | Genentech, Inc. | Predicting response to a HER dimerisation inhbitor based on low HER3 expression |
JP5117165B2 (ja) | 2007-11-09 | 2013-01-09 | 花王株式会社 | 水中油型乳化組成物の製造方法 |
JP5170667B2 (ja) | 2008-06-02 | 2013-03-27 | 小林クリエイト株式会社 | 情報隠蔽帳票 |
BRPI0812682A2 (pt) * | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
JP5213775B2 (ja) | 2009-03-25 | 2013-06-19 | 株式会社ジャパンディスプレイウェスト | 電気光学装置および電子機器 |
-
1998
- 1998-12-07 ZA ZA9811162A patent/ZA9811162B/xx unknown
- 1998-12-10 KR KR1020137005286A patent/KR20130036367A/ko not_active Application Discontinuation
- 1998-12-10 KR KR1020087018921A patent/KR20080075042A/ko not_active Application Discontinuation
- 1998-12-10 DK DK98963840.8T patent/DK1037926T3/da active
- 1998-12-10 CN CNB988120976A patent/CN1269839C/zh not_active Expired - Lifetime
- 1998-12-10 KR KR1020107028433A patent/KR20100135337A/ko not_active Application Discontinuation
- 1998-12-10 KR KR1020007006372A patent/KR20010033019A/ko not_active Application Discontinuation
- 1998-12-10 IL IL13620198A patent/IL136201A0/xx unknown
- 1998-12-10 CN CN200610008639XA patent/CN1820734B/zh not_active Ceased
- 1998-12-10 KR KR1020187027274A patent/KR20180107323A/ko not_active Application Discontinuation
- 1998-12-10 US US09/208,649 patent/US7846441B1/en not_active Expired - Fee Related
- 1998-12-10 KR KR1020127013045A patent/KR20120062942A/ko not_active Application Discontinuation
- 1998-12-10 EP EP98963840.8A patent/EP1037926B1/en not_active Revoked
- 1998-12-10 AU AU19081/99A patent/AU1908199A/en not_active Abandoned
- 1998-12-10 ES ES98963840.8T patent/ES2450922T3/es not_active Expired - Lifetime
- 1998-12-10 WO PCT/US1998/026266 patent/WO1999031140A1/en active Application Filing
- 1998-12-10 JP JP2000539062A patent/JP2002508397A/ja not_active Withdrawn
- 1998-12-10 CA CA2730373A patent/CA2730373A1/en not_active Abandoned
- 1998-12-10 CA CA2311409A patent/CA2311409C/en not_active Expired - Lifetime
- 1998-12-10 EP EP10178009A patent/EP2277919A1/en not_active Ceased
- 1998-12-10 TR TR2000/01689T patent/TR200001689T2/xx unknown
- 1998-12-10 EP EP10177992A patent/EP2275450A1/en not_active Withdrawn
- 1998-12-10 BR BR9815363-3A patent/BR9815363A/pt not_active Application Discontinuation
- 1998-12-10 KR KR1020147035850A patent/KR20150013870A/ko not_active Application Discontinuation
- 1998-12-11 AR ARP980106308A patent/AR020051A1/es unknown
-
2000
- 2000-05-17 IL IL136201A patent/IL136201A/en not_active IP Right Cessation
- 2000-05-17 NZ NZ504597A patent/NZ504597A/en not_active IP Right Cessation
- 2000-06-09 NO NO20002957A patent/NO20002957L/no unknown
-
2001
- 2001-03-06 HK HK01101597.4A patent/HK1030784A1/xx not_active IP Right Cessation
-
2003
- 2003-02-03 US US10/356,824 patent/US7892549B2/en not_active Expired - Fee Related
- 2003-04-04 US US10/406,925 patent/US20030170234A1/en not_active Abandoned
-
2004
- 2004-08-02 US US10/909,998 patent/US8642036B2/en not_active Expired - Lifetime
-
2006
- 2006-10-27 HK HK06111909.1A patent/HK1091391A1/xx not_active IP Right Cessation
-
2007
- 2007-07-20 US US11/780,640 patent/US8075892B2/en not_active Expired - Fee Related
-
2008
- 2008-01-04 US US11/969,465 patent/US20080187533A1/en not_active Abandoned
-
2009
- 2009-03-17 NO NO20091147A patent/NO20091147L/no not_active Application Discontinuation
-
2010
- 2010-04-07 JP JP2010088515A patent/JP2010209081A/ja active Pending
-
2011
- 2011-05-09 US US13/103,799 patent/US8309087B2/en not_active Expired - Fee Related
- 2011-07-14 IL IL214084A patent/IL214084A/en not_active IP Right Cessation
- 2011-07-18 US US13/185,329 patent/US8425908B2/en not_active Expired - Fee Related
-
2012
- 2012-10-04 JP JP2012222108A patent/JP2013056887A/ja not_active Withdrawn
-
2013
- 2013-03-15 US US13/841,146 patent/US20130209459A1/en not_active Abandoned
- 2013-12-26 US US14/141,232 patent/US20140341886A1/en not_active Abandoned
-
2014
- 2014-09-17 IL IL234696A patent/IL234696A/en not_active IP Right Cessation
-
2015
- 2015-06-09 JP JP2015116874A patent/JP2016006046A/ja not_active Withdrawn
-
2016
- 2016-09-23 JP JP2016185281A patent/JP2017039737A/ja active Pending
-
2017
- 2017-04-05 JP JP2017075241A patent/JP2017165737A/ja not_active Withdrawn
-
2018
- 2018-12-05 JP JP2018227941A patent/JP2019055979A/ja active Pending
-
2019
- 2019-04-23 US US16/392,300 patent/US20190240185A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA9811162B (en) | Treatment with anti-ERBB2 antibodies. | |
ZA200110263B (en) | Humanized anti-ERBB2 antibodies and treatment with anti-ERBB2 antibodies. | |
IL129354A0 (en) | Anti-ErbB2 antibodies | |
HK1016976A1 (en) | Resorcinyl-triazine. | |
EP0664969A3 (de) | Skischuh. | |
ZA959630B (en) | Diaminocyclobutene-3, 4-diones. | |
HK1017834A1 (en) | Bodyshaper. | |
EP0684299A3 (de) | Dihydrofarnesal. | |
ZA983705B (en) | Pregnan-3-ol-20-ones. | |
ZA968185B (en) | Protein. | |
GR3034943T3 (en) | Medrogestrone. | |
EP0672364A3 (de) | Skischuh. | |
ZA981309B (en) | 4-aminoalkoxy-1H-benzoimidazoles. | |
HK1017240A1 (en) | Clip. | |
EP0671133A3 (de) | Skischuh. | |
ZA983685B (en) | Pregnanes. | |
ZA983706B (en) | Pregnanes. | |
ZA98263B (en) | O-fucosyltransferase. | |
ZA983698B (en) | Estrenes. | |
AU2002301764A1 (en) | Treatment with anti-Erb2 antibodies | |
ZA972154B (en) | Stove. | |
ZA99815B (en) | Over-garment. | |
ZA982913B (en) | Estradienes. | |
ZA979554B (en) | Hydroscale. | |
ZA9811834B (en) | Substititued ß-alanines. |